Bitter medicine: Take corrective measures for the sake of our pharma exports

The US Food and Drug Administration’s (USFDA) ban on import of active pharmaceutical ingredients from Ranbaxy’s plant at Toansa in Punjab – in addition to three other of its earlier blacklisted manufacturing sites — has implications for more than just the beleaguered company. To start with, Ranbaxy Laboratories is not alone.

Read Full Story>>